Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinician's guide to hepatitis C

J B Gross1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, MN 55905, USA.

Mayo Clinic Proceedings
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) infection is a widespread, chronic condition often diagnosed late, leading to severe liver disease. Early screening and evolving combination therapies offer improved outcomes for patients with this silent epidemic.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Albinism in phylogenetically and geographically distinct populations of Astyanax cavefish arises through the same loss-of-function Oca2 allele.

Heredity·2013
Same author

Care of a parturient with preeclampsia, morbid obesity, and Crouzon's syndrome.

International journal of obstetric anesthesia·2008
Same author

Mutation in the ATP7A gene may not be responsible for hypocupraemia in copper deficiency myelopathy.

Postgraduate medical journal·2006
Same author

Non-responders to previous treatment for hepatitis C.

Minerva gastroenterologica e dietologica·2005
Same author

Hepatitis C: a sexually transmitted disease?

The American journal of gastroenterology·2001
Same author

Draeger Narkomed 6000 poses patient safety risks.

Anesthesiology·2001
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection is a significant global health concern, frequently asymptomatic and leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
  • Mortality rates associated with chronic hepatitis C are projected to rise substantially, highlighting the urgent need for effective management and prevention strategies.
  • Many infections remain undiagnosed due to a lack of awareness among both patients and healthcare providers, underscoring the importance of targeted screening.

Purpose of the Study:

  • To emphasize the critical need for screening at-risk populations for Hepatitis C virus infection.
  • To review current and emerging therapeutic strategies for managing chronic Hepatitis C.
  • To highlight the disparity in public funding for Hepatitis C virus research compared to other viral infections like HIV.

Related Experiment Videos

Main Methods:

  • Review of existing literature on Hepatitis C virus epidemiology, diagnosis, and treatment.
  • Analysis of current therapeutic efficacy and projected advancements in antiviral agents.
  • Comparison of funding models for viral disease research.

Main Results:

  • Hepatitis C virus infection is common, chronic, and often asymptomatic, posing a significant risk for liver cirrhosis and cancer.
  • Current interferon-based therapies offer limited sustained viral clearance (10-15%), with combination therapy (interferon and ribavirin) improving response rates to approximately 40%.
  • Future treatments may involve novel agents like protease inhibitors and multi-drug regimens, similar to HIV therapy, but research funding remains a challenge.

Conclusions:

  • Universal screening for Hepatitis C virus is recommended for all at-risk individuals, including those with transfusion history before 1992.
  • Treatment outcomes for Hepatitis C virus are improving with combination therapies, and further advancements are anticipated.
  • Increased public funding is crucial for accelerating the development of more effective Hepatitis C virus therapies and combating the growing burden of this disease.